	C_{max} (µg/ml)			AUC_{0-8} (µg·h/ml)			$t_{1/2}$ (µg·h/ml)		
	N	Mean (SD)	p-value	N	Mean (SD)	p-value	N	Mean (SD)	p-value
Age on day of PK									
0-6 months	20	7.73 (1.97)		20	25.88 (9.37)		19	2.11 (0.69)	
7-12 months	19	8.11 (1.79)	0,535	19	23.41 (7.27)	0,365	19	1.89 (0.69)	0,330
Nutritional status on day of PK									
≥-2.0	21	7.87 (2.17)		21	25.93 (10.62)		20	2.20 (0.85)	
<-2.0	18	7.96 (1.50)	0,885	18	23.22 (4.55)	0,297	18	1.77 (0.34)	0,046
Prematurity									
Term (38+ weeks)	24	8.12 (1.82)		24	25.10 (7.51)		23	1.96 (0.74)	
Premature (<37 weeks)	15	7.59 (1.95)	0,392	15	24.01 (9.89)	0,700	15	2.05 (0.61)	0,723
HIV status									
HIV-infected	5	7.95 (2.30)		5	21.97 (7.45)		5	1.73 (0.22)	
HIV-uninfected	34	7.91 (1.84)	0,967	34	25.08 (8.55)	0,446	33	2.04 (0.73)	0,071
Ethnicity									
African	29	8.11 (1.85)		29	25.36 (8.96)		29	2.03 (0.72)	
Mixed race	10	7.35 (1.90)	0,277	10	22.72 (6.49)	0,398	9	1.89 (0.58)	0,597
Gender									
Female	13	8.30 (1.81)		13	27.09 (10.20)		13	2.21 (0.72)	
Male	26	7.72 (1.90)	0,372	26	23.48 (7.26)	0,209	25	1.89 (0.66)	0,173

Table S1. Isoniazid pharmacokinetic parameters by age, nutritional status, prematurity, HIV status, ethnicity, and gender (n = 39)
WAZ, weight for age Z score, Cmax, maximum drug concentration in serum; AUC, the area under the concentration-time curve; t1/2, half-life of the drug; SD, standard deviation

	C_{max} (µg/ml)			AUC_{0-8} (µg·h/ml)			$t_{1/2}$ (µg·h/ml)		
	N	Mean (SD)	p-value	N	Mean (SD)	p-value	N	Mean (SD)	p-value
Age at PK sampling									
0-6 months	20	42.73 (11.29)		20	253.31 (82.68)		20	8.92 (3.52)	
7-12 months	19	40.94 (6.00)	0,539	19	224.66 (39.36)	0,175	18	7.01 (2.06)	0,047
Nutritional status on day of PK									
≥-2.0	21	39.37 (5.26)		21	214.72 (31.45)		21	7.83 (3.59)	
<-2.0	18	44.75 (11.55)	0,082	18	268.09 (83.45)	0,018	17	8.25 (2.29)	0,679
Prematurity									
Term (38+ weeks)	24	41.98 (8.69)		24	237.88 (60.51)		24	8.37 (3.55)	
Premature (<37 weeks)	15	41.66 (9.86)	0,917	15	241.71 (76.26)	0,863	14	7.41 (1.87)	0,285
HIV status									
HIV-infected	5	35.56 (4.99)		5	186.97 (27.05)		5	6.59 (1.71)	
HIV-uninfected	34	42.78 (9.17)	0,096	34	247.06 (66.77)	0,056	33	8.23 (3.16)	0,266
Ethnicity									
African	29	42.84 (9.08)		29	244.74 (71.57)		28	7.73 (2.27)	
Mixed race	10	38.99 (8.71)	0,250	10	223.74 (46.02)	0,393	10	8.82 (4.65)	0,489
Gender									
Female	13	40.84 (7.42)		13	229.69 (56.22)		13	7.92 (2.60)	
Male	26	42.36 (9.84)	0,626	26	244.18 (71.00)	0,526	25	8.06 (3.30)	0,892

Table S2. Pyrazinamide pharmacokinetic parameters by age, nutritional status, prematurity, HIV status, ethnicity, and gender (n = 39)
WAZ, weight for age Z score, Cmax, maximum drug concentration in serum; AUC, the area under the concentration-time curve; t1/2, half-life of the drug; SD, standard deviation

	C_{max} (µg/ml)			AUC_{0-8} (µg·h/ml)			$t_{1/2}$ (µg·h/ml)		
	N	Mean (SD)	p-value	N	Mean (SD)	p-value	N	Mean (SD)	p-value
Age at PK sampling									
0-6 months	10	1.33 (0.54)		10	5.29 (2.05)		9	3.79 (1.63)	
7-12 months	6	1.14 (0.43)	0,486	6	4.75 (1.66)	0,590	6	3.28 (1.20)	0,530
Nutritional status on day of PK									
≥-2.0	9	1.19 (0.52)		9	4.82 (1.80)		9	3.55 (1.56)	
<-2.0	7	1.35 (0.49)	0,543	7	5.43 (2.05)	0,540	6	3.65 (1.41)	0,903
Prematurity									
Term (38+ weeks)	10	1.11 (0.52)		10	4.48 (2.07)		9	3.49 (1.37)	
Premature (<37 weeks)	6	1.50 (0.38)	0,125	6	6.11 (0.87)	0,091	6	3.73 (1.69)	0,768
HIV status									
HIV-infected	2	0.39 (0.22)		2	2.04 (1.13)		2	3.32 (2.42)	
HIV-uninfected	14	1.38 (0.39)	0,004	14	5.52 (1.52)	0,008	13	3.63 (1.40)	0,791
Ethnicity									
African	11	1.23 (0.52)		11	4.83 (1.64)		10	3.64 (1.65)	
Mixed race	5	1.31 (0.49)	0,763	5	5.67 (2.41)	0,424	5	3.47 (1.11)	0,835
Gender									
Female	4	1.27 (0.33)		4	5.15 (1.19)		4	4.17 (2.08)	
Male	12	1.25 (0.55)	0,955	12	5.07 (2.10)	0,946	11	3.37 (1.21)	0,368

Table S3. Ethambutol pharmacokinetic parameters by age, nutritional status, prematurity, HIV status, ethnicity, and gender (n = 16)
WAZ, weight for age Z score, Cmax, maximum drug concentration in serum; AUC, the area under the concentration-time curve; t1/2, half-life of the drug; SD, standard deviation